for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cytokinetics, Inc.

CYTK.OQ

Latest Trade

11.60USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

5.76

 - 

14.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
11.60
Open
--
Volume
--
3M AVG Volume
9.58
Today's High
--
Today's Low
--
52 Week High
14.91
52 Week Low
5.76
Shares Out (MIL)
58.68
Market Cap (MIL)
656.03
Forward P/E
-5.51
Dividend (Yield %)
--

Next Event

Q3 2019 Cytokinetics Inc Earnings Release

Latest Developments

More

Cytokinetics Inc says May Offer And Sell Additional Shares Of Co's Common Stock Of Up To $50 Million From Time To Time

Cytokinetics Says Q2 Loss Per Share $0.56

Millennium Management Reports 5.3% Passive Stake In Cytokinetics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cytokinetics, Inc.

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.

Industry

Biotechnology & Drugs

Contact Info

280 E Grand Ave

+1.650.6243000

http://cytokinetics.com/

Executive Leadership

Leonard Patrick Gage

Independent Chairman of the Board

Robert I. Blum

President, Chief Executive Officer, Director

Ching Jaw

Chief Financial Officer, Senior Vice President

David W. Cragg

Chief Human Resource Officer, Chief Administrative Officer

Fady Ibraham Malik

Executive Vice President - Research and Development

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

0.390

2017

-2.590

2018

-1.950

2019(E)

-2.023
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.42
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-55.51
Return on Equity (TTM)
-49.37

Latest News

Latest News

BRIEF-Cytokinetics Reports Q1 Loss Per Share Of $0.56

* CYTOKINETICS, INC. REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytokinetics Qtrly Net Loss Per Share $0.75

* CYTOKINETICS, INC. REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Cytokinetics Announces Progress Against Vision 2020

* CYTOKINETICS INC - RESULTS FROM FOUR CLINICAL TRIALS OF CK-2127107 EXPECTED IN 2018

Cytokinetics sinks on abandoning ALS drug after failed trial

Cytokinetics Inc shares plummeted nearly 28 percent on Tuesday after the drugmaker said it would stop developing one of its treatments for ALS, a fatal neuro-degenerative disorder, after the drug failed to improve lung function in a key trial.

BRIEF-Cytokinetics Inc announces negative results from VITALITY-ALS

* Phase 3 clinical trial of Tirasemtiv in patients with ALS did not meet primary or secondary endpoints

Cytokinetics' neuro-degenerative drug fails late-stage trial

Cytokinetics Inc said on Tuesday its drug to treat a type of neuro-degenerative disorder failed to meet the main goal of a late-stage trial.

BRIEF-Cytokinetics files for potential mixed shelf, size undisclosed

* Cytokinetics Inc files for potential mixed shelf, size undisclosed - SEC Filing Source text: http://bit.ly/2hauCBo Further company coverage:

BRIEF-Cytokinetics enters into second amendment to certain loan and security agreement

* Cytokinetics - on Oct 27, entered into second amendment to certain loan and security agreement dated as of October 19, 2015

BRIEF-Cytokinetics reports Q3 loss of ‍$0.60/shr​

* Cytokinetics, Inc. reports third quarter 2017 financial results

BRIEF-Cytokinetics announces dosing of first patient in Japan in phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

* Cytokinetics announces dosing of first patient in Japan in GALACTIC-HF, phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure

BRIEF-Cytokinetics announces additional results from COSMIC-HF at HFSA 21st Annual Scientific Meeting

* Cytokinetics announces presentation of additional results from COSMIC-HF at the HFSA 21st Annual Scientific Meeting Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics Q2 loss per share $0.60

* Cytokinetics Inc reports second quarter 2017 financial results

BRIEF-Cytokinetics announces positive results from phase 2 trial of Omecamtiv Mecarbil

* Cytokinetics announces positive results from phase 2 clinical trial of Omecamtiv Mecarbil in Japanese patients with heart failure

BRIEF-Cytokinetics announces start of FORTITUDE-ALS

* Cytokinetics announces start of fortitude-als, a phase 2 clinical trial of ck-2127107 in patients with amyotrophic lateral sclerosis Source text for Eikon: Further company coverage:

BRIEF-Cytokinetics reports baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with SMA

* Cytokinetics announces baseline data from first cohort of phase 2 clinical trial of ck-2127107 in patients with sma

BRIEF-Cytokinetics starts phase 1B clinical trial of CK-2127107 in elderly subjects

* Cytokinetics announces start of phase 1B clinical trial of CK-2127107 in elderly subjects with limited mobility

BRIEF-Cytokinetics announces orphan drug designation for CK-2127107 for treatment of spinal muscular atrophy

* Cytokinetics announces orphan drug designation for CK-2127107 for the treatment of spinal muscular atrophy

BRIEF-Cytokinetics announces results from dose escalation phase of Cosmic-HF

* Cytokinetics announces results from dose escalation Phase of Cosmic-HF

BRIEF-Cytokinetics Q1 loss per share $0.62

* Cytokinetics, inc. Reports first quarter 2017 financial results

BRIEF-Cytokinetics announces start of second cohort in Phase 2 clinical trial of CK-2127107

* Cytokinetics announces start of second cohort in phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up